Oxford Bioscience Partners is a global venture capital firm that focuses on investing in the life sciences, technology, energy, and healthcare sectors. The firm typically participates in various stages of funding, including Series A, B, C, D, and beyond, with a notable presence in Series B rounds. Their investments span a wide range of companies worldwide, reflecting their broad industry focus and commitment to fostering innovation across multiple sectors.
Notable portfolio companies include Accelerated Technologies, Adastra Pharmaceuticals, BrainCells, Cambrios Technologies, and CardioFocus. Key decision-makers at Oxford Bioscience Partners bring extensive experience and industry connections to the table, enhancing the firm's ability to support its portfolio companies. The firm prides itself on offering unique value-add services, such as strategic guidance and leveraging their global network to help startups scale effectively.
Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Top Investment Stages
Stage Mix
Concentration shown as share of disclosed investments by stage.
Classification
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
